DDInter93 DDInter740
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Anagrelide {u} (Compound) upregulates {v} (Gene) CDK6
CDK6 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Anagrelide {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Flecainide
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Mefloquine
Mefloquine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Anagrelide {u} (Compound) upregulates {v} (Gene) CDK6
CDK6 {u} (Gene) regulates {v} (Gene) RRM2
RRM2 {u} (Gene) is downregulated by {v} (Compound) Flecainide
Anagrelide {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Anagrelide {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Mefloquine
Mefloquine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Anagrelide {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is regulated by {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Anagrelide {u} (Compound) upregulates {v} (Gene) CDK6
CDK6 {u} (Gene) is regulated by {v} (Gene) GJA1
GJA1 {u} (Gene) is downregulated by {v} (Compound) Flecainide
Anagrelide may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)
Anagrelide (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Flecainide (Compound)
Anagrelide (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Flecainide (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Anagrelide (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) regulates RRM2 (Gene) and RRM2 (Gene) is downregulated by Flecainide (Compound)
Anagrelide (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Anagrelide (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Flecainide (Compound)
Anagrelide (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is regulated by MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Flecainide (Compound)
Anagrelide (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is regulated by GJA1 (Gene) and GJA1 (Gene) is downregulated by Flecainide (Compound)